Litcius/Paper detail

Mosaic RBD nanoparticle elicits immunodominant antibody responses across sarbecoviruses

Chuanyu Liu, Senyu Xu, Yuxuan Zheng, Yufeng Xie, Kun Xu, Yan Chai, Tingrong Luo, Lianpan Dai, George F. Gao

2024Cell Reports20 citationsDOIOpen Access PDF

Abstract

Nanoparticle vaccines displaying mosaic receptor-binding domains (RBDs) or spike (S) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or other sarbecoviruses are used in preparedness against potential zoonotic outbreaks. Here, we describe a self-assembling nanoparticle using lumazine synthase (LuS) as the scaffold to display RBDs from different sarbecoviruses. Mosaic nanoparticles induce sarbecovirus cross-neutralizing antibodies comparable to a nanoparticle cocktail. We find mosaic nanoparticles elicit a B cell receptor repertoire using an immunodominant germline gene pair of IGHV14-3:IGKV14-111. Most of the tested IGHV14-3:IGKV14-111 monoclonal antibodies (mAbs) are broadly cross-reactive to clade 1a, 1b, and 3 sarbecoviruses. Using mAb competition and cryo-electron microscopy, we determine that a representative IGHV14-3:IGKV14-111 mAb, M2-7, binds to a conserved epitope on the RBD, largely overlapping with the pan-sarbecovirus mAb S2H97. This suggests mosaic nanoparticles expand B cell recognition of the common epitopes shared by different clades of sarbecoviruses. These results provide immunological insights into the cross-reactive responses elicited by mosaic nanoparticles against sarbecoviruses.

Topics & Concepts

VirologyAntibodyMosaicBiologyChemistryCell biologyComputational biologyImmunologyGeographyArchaeologyAnimal Virus Infections StudiesVirus-based gene therapy researchSARS-CoV-2 and COVID-19 Research